Bristol Myers Squibb to acquire Orbital Therapeutics for $1.5bn.

Bristol Myers Squibb, a company active in pharmaceuticals and cell therapy, agreed to acquire Orbital Therapeutics, a biotechnology company, for $1.5bn. “This agreement with Bristol Myers Squibb, a recognized leader in global medicine, marks a transformational moment for Orbital and the advancement of RNA medicine. Since inception, Orbital has made significant strides developing a differentiated RNA platform designed to enable a new generation of RNA medicines that reach more tissues, address more diseases, and benefit more patients. The promising early data from our lead program, OTX-201, underscore the strength of this approach and the potential of our integrated RNA technologies. Together, we aim to deliver RNA medicines that provide patients with treatments that are simpler, safer, and more accessible compared to today’s complex therapies,” Ron Philip, Orbital Therapeutics Chief Executive Officer.